Disclosures: Suzanne George has received institutional research funding from Blueprint Medicines, Deciphera Pharmaceuticals, Merck, Eisai, Tracon, BioAtla, Theseus, IDRx, NewBay; has held advisory board/consultant roles for Deciphera Pharmaceuticals, NewBay, Alexion and scientific advisory board for Kayothea; has received honoraria from C-stone Pharmaceuticals; has received compensation as DSMB Chair from WCG; has received royalties from Wolter Kluwers Health (UptoDate); has held equity from Abbott Labs, Pfizer (Dec 2023 - Mar 2024); has held leadership positions as Interim Group Chair Alliance for Clinical Trials in Oncology (end date Nov 2023) and President Alliance Foundation (end date Dec 2023). Sebastian Bauer has received institutional research funding from Incyte, Blueprint Medicines, and von Pfeffel pharmaceuticals; has held a scientific advisory role (non-compensated) for IDRX, von Pfeffel, and Deciphera; received honoraria (CME) from Deciphera; and held an advisory role for Adcendo, Boehringer Ingelheim, and Cogent. Paulina Cox was employed by Deciphera Pharmaceuticals, LLC at the time of publication development. Kam Sprott is an employee of Deciphera Pharmaceuticals, LLC. Carolina Larrain, Tracey Pu, and Andrew M. Blakely have no conflicts of interest to declare that may be relevant to the contents of this research.